Anna Norhammar

Anna Norhammar

Auto-generated profile, based on publicly available information

Anna Norhammar

Division of Cardiology, Department of Medicine Solna Karolinska Institute Stockholm Sweden

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in The Lancet
Verified
Journal Article
Closed access
ANAnna Norhammar
Anna Norhammar
ÅTÅke Tenerz
Åke Tenerz
GNGöran Nilsson
Göran Nilsson
AHAnders Hamsten
Anders Hamsten
SESuad Efendíc
Suad Efendíc
KMKlas Malmberg
Klas Malmberg

18 July 2017 in Circulation
Verified
Journal Article
Open access
PDF file
MKMikhail Kosiborod
Mikhail Kosiborod
MCMatthew A. Cavender
Matthew A. Cavender
AFAlex Z. Fu
Alex Z. Fu
JWJohn Wilding
John Wilding
KKKamlesh Khunti
Kamlesh Khunti
PFPeter Fenici
Peter Fenici
Background: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease. We compared HHF and death in patients newly initiated on any SGLT-2i versus other glucose-lowering drugs in 6 countries to determine if these benefits are seen in real-world practice and across SGLT-2i class. Methods: Data were collected via medical claims, primary care/hospital records, and national registries from the United States, Norway, Denmark, Sweden, Germany, and the United Kingdom. Propensity score for SGLT-2i initiation was used to match treatment groups. Hazard ratios for HHF, death, and their combination were estimated by country and pooled to determine weighted effect size. Death data were not available for Germany. Results: After propensity matching, there were 309 056 patients newly initiated on either SGLT-2i or other glucose-lowering drugs (154 528 patients in each treatment group). Canagliflozin, dapagliflozin, and empagliflozin accounted for 53%, 42%, and 5% of the total exposure time in the SGLT-2i class, respectively. Baseline characteristics were balanced between the 2 groups. There were 961 HHF cases during 190 164 person-years follow-up (incidence rate, 0.51/100 person-years). Of 215 622 patients in the United States, Norway, Denmark, Sweden, and the United Kingdom, death occurred in 1334 (incidence rate, 0.87/100 person-years), and HHF or death in 1983 (incidence rate, 1.38/100 person-years). Use of SGLT-2i, versus other glucose-lowering drugs, was associated with lower rates of HHF (hazard ratio, 0.61; 95% confidence interval, 0.51–0.73; P <0.001); death (hazard ratio, 0.49; 95% confidence interval, 0.41–0.57; P <0.001); and HHF or death (hazard ratio, 0.54; 95% confidence interval, 0.48–0.60; P <0.001) with no significant heterogeneity by country. Conclusions: In this large multinational study, treatment with SGLT-2i versus other glucose-lowering drugs was associated with a lower risk of HHF and death, suggesting that the benefits seen with empagliflozin in a randomized trial may be a class effect applicable to a broad population of patients with type 2 diabetes mellitus in real-world practice. Clinical Trial Registration: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02993614.

25 May 1999 in Circulation
Verified
Journal Article
Closed access
PDF file
KMKlas Malmberg
Klas Malmberg
ANAnna Norhammar
Anna Norhammar
HWHans Wedel
Hans Wedel
LRLars Rydén
Lars Rydén
Background —The Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study addressed prognostic factors and the effects of concomitant treatment and glycometabolic control in diabetic patients with myocardial infarction (AMI). Methods and Results —Of 620 diabetic patients with AMI, 306 were randomly assigned to a ≥24-hour insulin-glucose infusion followed by multidose subcutaneous insulin. Three hundred fourteen patients were randomized as controls, receiving routine antidiabetic therapy. Thrombolysis and β-blockers were administered when possible. Univariate and multivariate statistical analyses were applied to study predictors of long-term mortality. During an average follow-up of 3.4 years (range, 1.6 to 5.6 years), 102 patients (33%) in the intensive insulin group and 138 (44%) in the control group died ( P =0.011). Old age, previous heart failure, diabetes duration, admission blood glucose, and admission Hb A Ic were independent predictors of mortality in the total cohort, whereas previous AMI, hypertension, smoking, or female sex did not add independent predictive value. Metabolic control, mirrored by blood glucose and Hb A Ic , improved significantly more in patients on intensive insulin treatment than in the control group. β-Blockers improved survival in control subjects, whereas thrombolysis was most efficient in the intensive insulin group. Conclusions —Mortality in diabetic patients with AMI is predicted by age, previous heart failure, and severity of the glycometabolic state at admission but not by conventional risk factors or sex. Intensive insulin treatment reduced long-term mortality despite high admission blood glucose and Hb A Ic .

1 September 2017 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
KBKåre I Birkeland
Kåre I Birkeland
MJMarit E Jørgensen
Marit E Jørgensen
BCBendix Carstensen
Bendix Carstensen
FPFrederik Persson
Frederik Persson
HGHanne L Gulseth
Hanne L Gulseth
ANAnna Norhammar
Anna Norhammar

9 February 2016 in Circulation
Verified
Journal Article
Closed access
LRLars Rydén
Lars Rydén
KBKåre Buhlin
Kåre Buhlin
EEEva Ekstrand
Eva Ekstrand
UFUlf de Faire
Ulf de Faire
AGAnders Gustafsson
Anders Gustafsson
BKBjörn Klinge
Björn Klinge
Background—: The relationship between periodontitis (PD) and cardiovascular disease is debated. PD is common in patients with cardiovascular disease. It has been postulated that PD could be causally related to the risk for cardiovascular disease, a hypothesis tested in the Periodontitis and Its Relation to Coronary Artery Disease (PAROKRANK) study. Methods and Results—: Eight hundred five patients (<75 years of age) with a first myocardial infarction (MI) and 805 age- (mean 62±8), sex- (male 81%), and area-matched controls without MI underwent standardized dental examination including panoramic x-ray. The periodontal status was defined as healthy (≥80% remaining bone) or as mild-moderate (from 79% to 66%) or severe PD (<66%). Great efforts were made to collect information on possibly related confounders (≈100 variables). Statistical comparisons included the Student pairwise t test and the McNemar test in 2×2 contingency tables. Contingency tables exceeding 2×2 with ranked alternatives were tested by Wilcoxon signed rank test. Odds ratios (95% confidence intervals) were calculated by conditional logistic regression. PD was more common (43%) in patients than in controls (33%; P <0.001). There was an increased risk for MI among those with PD (odds ratio, 1.49; 95% confidence interval, 1.21–1.83), which remained significant (odds ratio, 1.28; 95% confidence interval, 1.03–1.60) after adjusting for variables that differed between patients and controls (smoking habits, diabetes mellitus, years of education, and marital status). Conclusions—: In this large case–control study of PD, verified by radiographic bone loss and with a careful consideration of potential confounders, the risk of a first MI was significantly increased in patients with PD even after adjustment for confounding factors. These findings strengthen the possibility of an independent relationship between PD and MI.

1 February 2004 in JACC
Verified
Journal Article
Closed access
ANAnna Norhammar
Anna Norhammar
KMKlas Malmberg
Klas Malmberg
EDErik Diderholm
Erik Diderholm
BLBo Lagerqvist
Bo Lagerqvist
BLBertil Lindahl
Bertil Lindahl
LWLars Wallentin
Lars Wallentin